---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127054"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:17:46.876861+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma reports $26.9M cash, no debt; continues strategic alternatives review

## Summary
- Cash, cash equivalents and short-term investments at Sept 30, 2024: $26.9M; no outstanding debt.
- Strategic alternatives review ongoing; Oppenheimer & Co. acting as exclusive financial advisor.
- Reduction-in-force initiated as part of cash preservation efforts; further stages planned.
- No assurance that any transaction will result; updates only if Board determines disclosure appropriate.

## SEC filing metadata
- accession: 0000950170-24-127054
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017024127054/0000950170-24-127054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017024127054/meip-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127054
- JSON: https://secwatch.observer/filing/0000950170-24-127054.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.